

24 August 2021
EFPIA Japan

Takahiko Iwaya to chair EFPIA Japan

TOKYO – 24 August 2021 – EFPIA Japan announced today that Takahiko Iwaya (Sanofi K.K.) has been appointed the new chair of EFPIA Japan, effective 1 September 2021. Current Chair Heike Prinz will resign due to her new appointment outside the country in Bayer.

Yoshiaki Aono (Nippon Boehringer Ingelheim Co., Ltd.) who continues in his current position as vice chair, and Leo Lee (Novartis Pharma K.K.) who has been newly appointed vice chair will support Takahiko Iwaya in his new role.

Takahiko Iwaya, who will assume the new chair of EFPIA Japan, says, "As a super-aging society, Japan has to address increasing diversified healthcare needs, while also responding to urgent public health challenges as a result of the COVID-19 pandemic. In order to strengthen the healthcare system and promote innovation, it is important that EFPIA Japan continues to work closely with our partners and facilitate constructive discussions between the government and industry. I am honored and truly humbled to be appointed as chair of EFPIA Japan and will make the most of my experience working as a government official and in the pharmaceutical industry to help fulfill the mission of EFPIA."

EFPIA Japan Board Members as of 1 September 2021

Chair	Takahiko Iwaya (Sanofi K.K.)	New
Vice Chairs	Yoshiaki Aono (Nippon Boehringer Ingelheim Co., Ltd.)	
	Leo Lee (Novartis Pharma K.K.)	New
Board of Directors	Ole Mølskov Bech (Novo Nordisk Pharma Ltd.)	
	Stefan Woxström (AstraZeneca K.K.)	
	Paul Lirette (GlaxoSmithKline K.K.)	
	Julio Triana (Bayer Yakuhin, Ltd.)	New
	Alexandre De Muralt (Merck Biopharma Co., Ltd.)	
	Kanako Kikuchi (UCB Japan Co., Ltd.)	
Director General	Yasuhiro Nishimi (Nippon Boehringer Ingelheim Co., Ltd.)	



European Federation of Pharmaceutical
Industries and Associations

About EFPIA Japan (<http://efpia.jp/>)

Established in April 2002, EFPIA Japan represents 21 R&D-based European pharmaceutical companies operating in Japan. In 2020, combined sales from the member companies accounted for roughly 23% of the pharmaceutical market in Japan. The mission of EFPIA Japan is to “Contribute to healthcare and patients in Japan through the early introduction of innovative medicines and vaccines”. EFPIA Japan aims to strengthen dialogue with decision-makers in order to improve Japanese healthcare for all.

About EFPIA (European Federation of Pharmaceutical Industries and Associations)

(<http://www.efpia.eu>)

EFPIA, EFPIA Japan’s partner organisation, is headquartered in Brussels and represents the pharmaceutical industry operating in Europe. Through its direct membership of 36 national associations and 39 leading pharmaceutical companies, EFPIA provides the voice of companies committed to researching, developing and bringing new medicines to improve health and quality of life around the world.

Contact:

Yuko Kidoguchi

EFPIA Japan Messaging & Communications Committee

1-6-5 Marunouchi Chiyoda-ku, Tokyo 100-8268

Bayer Holding Ltd.

Tel: 03-6266-7757

Email: yuko.kidoguchi@bayer.com

EFPIA Japan

ThinkPark Tower, 2-1-1, Osaki, Shinagawa-ku, Tokyo 141-6017, Japan

Tel: +81-3- 6417-2032

Fax: +81-3- 6685-4870